hrp0097rfc3.1 | Fat, metabolism and obesity 1 | ESPE2023

Fasting and meal-related zonulin serum levels in a large cohort of obese children and adolescents: a cross sectional study

Pepe Giorgia , Corica Domenico , Currò Monica , Aversa Tommaso , Alibrandi Angela , Bottari Marianna , Ientile Riccardo , Caccamo Daniela , Wasniewska Malgorzata

Background: due to its recently documented role in intercellular tight junction disassembly, zonulin has emerged as a valuable biological marker to assess the integrity of the intestinal mucosal barrier. Experimental studies have shown an association between intestinal permeability and obesity.Objectives: aim of this study was to investigate the relationship between serum zonulin levels, both at baseline and postprandial...

hrp0084p1-60 | DSD | ESPE2015

Insight into the Human Ovarian Sex Development Networks

Bouazzi Leila , Franco Mariangela , Eid Wassim , Meyer-Boni Monika , Sproll Patrick , Maret Alexander , Lauber-Biason Anna

Background: Ovarian sex differentiation network involves a panoply of interacting factors. Yet, no single sex-determining factor has been identified to be an equivalent of SRY or SOX9 in the testis. Recently, data suggested CBX2 as a pioneer regulator promoting testis development. In addition to its implication in ovary pathway differentiation which remains unclear.Objective and hypotheses: To deepen our understanding of the regulatory network that under...

hrp0095p1-508 | Growth and Syndromes | ESPE2022

Real-world experience with Vosoritide for achondroplasia: interim findings from an early access programme in France

Cormier-Daire Valérie , Cohen Shelda , Edouard Thomas , Isidor Bertrand , Mukherjee Swati , Pimenta Jeanne , Rossi Massimiliano , Schaefer Elise , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide (once daily, subcutaneous injection) has recently been approved by the European Medicines Agency (EMA) for treating achondroplasia in patients aged ≥2 years until closure of epiphyses. It has been made available in France via an early access program, a cohort Temporary Authorization fo...

hrp0084p2-517 | Pituitary | ESPE2015

Be Aware of Congenital Panhypopituitarism in Children with a Family History of Polydactyly

Hovinga Idske Kremer , Giltay Jacques , van der Kamp Hetty

Background: Congenital panhypopituitarism is associated with a variety of gene mutations. Abnormalities in the Gli2 gene were only recently described to be associated with congenital panhypopituitarism (Franca et al. 2010). Gli2 is a gene that encodes a transcription factor downstream of the Sonic Hedgehog pathway – known to play an important role in morphogenesis during embryology.Objective and hypotheses: Although Gli2 mutations were described to ...

hrp0086p2-p844 | Syndromes: Mechanisms and Management P2 | ESPE2016

Growth Screening in Children Aged Three to Five Years Seen in Community Paediatrics in Dreux District, France: Preliminary Results

Kayemba-Kay's Simon , Brin Isabelle , Nicot Florence , Maillet Odile , Roudiere Jean-Louis , Nicola Luigi Di , Heron Anne

Background: Over 90% children grow normally, and attain final height within their genetic target. Up to 10% of all children do not spontaneously catch-up by the age 3 years, besides some cases of TS are diagnosed late, and others with SGA go undiagnosed and unattended.Objectives & Hypothesis: Early screening of growth patterns in children attending Child Protection Visits (PMI, France) in Dreux district. Our objective was the evaluation of prevalence...

hrp0084p3-956 | GH & IGF | ESPE2015

A 5-year Follow-up of Adults, with Childhood-Onset GH Deficiency, Treated with GENOTONORM® in France

Touraine Philippe , Borson-Chazot Francoise , Delemer Brigitte , Brue Thierry

Background: Young adult patients with childhood-onset GH deficiency (GHD) whose GH replacement therapy (GHRT) is discontinued exhibit negative metabolic and physiological effects, reversible through GHRT.Objective and hypotheses: To report the characteristics and 5-year GHRT in adults with childhood-onset GHD.Method: Analysis of the subgroup of adults with childhood-onset GHD included between March 2003 and October 2006 in KIMS. In...

hrp0097rfc4.5 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Real-world safety and effectiveness of vosoritide: Results from an early access program in France

Cormier-Daire Valérie , Edouard Thomas , Isidor Bertrand , Cohen Shelda , Mukherjee Swati , Pimenta Jeanne , Lhaneche Leila , Rossi Massimiliano , Schaefer Elise , Goodman Erin , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is the most common skeletal dysplasia, in which the main clinical feature is short stature. Vosoritide, the first specific treatment for achondroplasia; administered as a daily subcutaneous injection, was approved by the European Medicines Agency in August 2021 for patients aged ≥2 years until closure of epiphyses. French Health Authorities granted early access to vosoritide treatment in France on 24 June 2021, which continued u...

hrp0095p1-81 | Fat, Metabolism and Obesity | ESPE2022

The relationship between body mass index, adipose indices measured by whole-body DXA and markers of cardio-metabolic risk in survivors of childhood medulloblastoma

Cima Luminita-Nicoleta , Iliescu Marina , Soare Iulia , Nedelea Lavinia , Oprescu Raluca , Tarna Mihaela , Comsa Codruta , Dragomir Monica , Gabriela Barbu Carmen , Fica Simona

Background: Endocrine disturbances are the most prevalent complications in childhood cancer survivors (CSS), especially in those treated with cranial and cervical radiation for brain tumours, such as medulloblastoma. Recent data have shown frequent delays in the diagnosis and treatment of these complications that may lead to potential side-effects on general health. Apart from the well-known hypothalamic–pituitary and growth disorders observed in CSS, th...

hrp0092p2-46 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Seasonal 25-hydroxy Vitamin D3 Variations in School-aged Children from Santiago de Chile

Poggi Helena , Dominguez Gonzalo , Monica Arancibia , Moore Rosario , D'Apremont Ivonne , Solari Sandra , Allende Fidel , Sifaqui Sofia , Garcia Hernan , Martinez-Aguayo Alejandro

Introduction: The main role of Vitamin D (VitD) is the regulation of calcium, which is also regulated by the parathyroid hormone (PTH), and phosphate metabolism. The main source of the more biologically active 25-hydroxy-Vitamin D3 (25OHVitD3) comes from the action of ultraviolet light on the skin.Aim: To determine if there are differences in concentrations of 25OHVitD3, calcium and PTH in school-aged children throughout...

hrp0089p2-p138 | Fat, Metabolism and Obesity P2 | ESPE2018

Physical Activity Determined by Accelerometry Before and After an Integral Treatment Program in Children with Abdominal Obesity

Azcona Maria Cristina , Morell Lydia , Ochotorena Amaia , Ana Ojeda , Leon Jose Luis , Prados Monica , Chueca Maria , Marti Amelia , GenoI Other members Grupo

Introduction: Physical activity (PA) is one of the treatments to promote weight loss in children with obesity. The WHO advices to perform moderate to vigorous (MV) PA during 60-min daily. It is necessary to measure the effect of increasing PA and the adherence to therapy.Aims: To evaluate PA using accelerometry at the onset and after 8 weeks of treatment with nutritional intervention and increase in PA.Patients, material and method...